Medivir AB
Company Profile
Business description
Medivir AB develops drugs with a focus on cancer, where unmet medical needs are high. The company is concentrating on the development of fostroxacitabine bralpamide (fostrox), a liver-targeted inhibitor of DNA replication that selectively delivers the cell-killing agent to the tumor while minimizing potentially harmful effects on normal cells. It has developed two pharmaceutical products: Xerclear, used for treating labial herpes (cold sores), and Olysio, which have reached the market. Medivir also has various out-licensed projects, such as MIV-701, birinapant, USP-1/TNG348, USP-7, and MBLI/MET-X, as well as two other drug projects, remetinostat and MIV-711, in the clinical development phase. Geographically, it generates its maximum revenue from Europe and other regions.
Contact
Lunastigen 5
PO Box 1086, 2nd floor
Huddinge141 22
SWET: +46 854683100
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
10
Stocks News & Analysis
stocks
Why I dislike dividend stocks
stocks
Chart of the Week: Ramsay Health Care margins to rebound
stocks
BlackRock earnings: Market gains and inflows drive AUM and revenue to record highs
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,375.90 | 19.70 | 0.21% |
| CAC 40 | 8,184.94 | 107.94 | 1.34% |
| DAX 40 | 24,278.83 | 97.46 | 0.40% |
| Dow JONES (US) | 46,368.32 | 115.01 | 0.25% |
| FTSE 100 | 9,434.07 | 9.32 | 0.10% |
| HKSE | 25,888.51 | 22.09 | -0.09% |
| NASDAQ | 22,804.29 | 134.21 | 0.59% |
| Nikkei 225 | 48,277.74 | 605.07 | 1.27% |
| NZX 50 Index | 13,389.10 | 81.70 | 0.61% |
| S&P 500 | 6,693.16 | 22.10 | 0.33% |
| S&P/ASX 200 | 9,068.40 | 18.20 | 0.20% |
| SSE Composite Index | 3,916.23 | 4.02 | 0.10% |